NANOPARTICLE DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR PXD101 FACILITATES BLADDER CANCER CELL UPTAKE AND CYTOTOXICITY

被引：0
|
作者：
Kaimakliotis, Hristos Z.
Martin, Darryl T.
Hoimes, Christopher J.
Cheng, Christopher C.
Liu, Jingchun
Kelly, Wm. Kevin
Tew, Gregory N.
Saltzman, W. Mark
Weiss, Robert M.
机构：
来源：
JOURNAL OF UROLOGY | 2011年 / 185卷 / 04期
关键词：
D O I：
10.1016/j.juro.2011.02.1180
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
1358
引用
收藏
页码：E542 / E542
页数：1
相关论文
共 50 条
  • [1] The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
    Buckley, Michael T.
    Yoon, Joanne
    Yee, Herman
    Chiriboga, Luis
    Liebes, Leonard
    Ara, Gulshan
    Qian, Xiaozhong
    Bajorin, Dean F.
    Sun, Tung-Tien
    Wu, Xue-Ru
    Osman, Iman
    JOURNAL OF TRANSLATIONAL MEDICINE, 2007, 5 (1)
  • [2] The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
    Michael T Buckley
    Joanne Yoon
    Herman Yee
    Luis Chiriboga
    Leonard Liebes
    Gulshan Ara
    Xiaozhong Qian
    Dean F Bajorin
    Tung-Tien Sun
    Xue-Ru Wu
    Iman Osman
    Journal of Translational Medicine, 5
  • [3] Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment
    Lin, Shu-Fu
    Lin, Jen-Der
    Chou, Ting-Chao
    Huang, Yu-Yao
    Wong, Richard J.
    PLOS ONE, 2013, 8 (10):
  • [4] Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
    Qian, Xiaozhong
    LaRochelle, William J.
    Ara, Gulshan
    Wu, Frank
    Petersen, Kamille Dumong
    Thougaard, Annemette
    Sehested, Maxwell
    Lichenstein, Henri S.
    Jeffers, Michael
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (08) : 2086 - 2095
  • [5] Activity of the histone deacetylase (HDAC) inhibitor PXD101 in preclinical prostate cancer studies
    Jeffers, M.
    Qian, X.
    Mills, E.
    LaRochelle, W.
    Lichenstein, H.
    Ara, G.
    EJC SUPPLEMENTS, 2006, 4 (12): : 109 - 109
  • [6] Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer
    Qian, Xiaozhong
    Ara, Gulshan
    Mills, Evan
    LaRochelle, William J.
    Lichenstein, Henri S.
    Jeffers, Michael
    INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (06) : 1400 - 1410
  • [7] The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
    Ma, Brigette B. Y.
    Sung, Fion
    Tao, Qian
    Poon, Fan Fong
    Lui, Vivian W.
    Yeo, Winnie
    Chan, Stephen L.
    Chan, Anthony T. C.
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (02) : 107 - 114
  • [8] Activity of the histone deacetylase (HDAC) inhibitor PXD101 in preclinical ovarian cancer studies.
    Qian, XZ
    LaRochelle, WJ
    Ara, G
    Wu, F
    Petersen, KD
    Thougaard, A
    Sehested, M
    Lichenstein, HS
    Jeffers, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9080S - 9080S
  • [9] The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
    Brigette B.Y. Ma
    Fion Sung
    Qian Tao
    Fan Fong Poon
    Vivian W. Lui
    Winnie Yeo
    Stephen L. Chan
    Anthony T.C. Chan
    Investigational New Drugs, 2010, 28 : 107 - 114
  • [10] Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
    N. L. Steele
    J. A. Plumb
    L. Vidal
    J. Tjørnelund
    P. Knoblauch
    P. Buhl-Jensen
    R. Molife
    R. Brown
    J. S. de Bono
    T. R. J. Evans
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1273 - 1279
12345